ClinicalTrials.gg
RecruitingNCT07945288Updated Nov 18, 2026

Safety and Feasibility of an Integrated Fabric-Type Orthosis for Gait and Balance Improvement in Geriatric Patients

An interventional study of Integrated Fabric-Type Orthosis in Sarcopenia, Older Adults (65 Years and Older) and Gait Analysis, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 41 studies in Sarcopenia with a site in Korea, Republic of — 14 open to participants now, 16 under way, none of them phase 3. Sarcopenia · Korea, Republic of.

Planned enrollment
28th of 30
30 · median 80
Started
2026
with 3 others
No phase
20 of 41
7 open now
Primary completion
2027-12
later than 13 of 15 live
Registered
38th of 41
by date
Lead sponsor
5 of 41
Seoul National University Hospital

Among the 41 studies in Sarcopenia with a site in Korea, Republic of, this one is the 28th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 with no phase, reaches primary completion later than 13 of the 15 other live ones, and was the 38th registered.

Sarcopenia

1,331 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

14 of the 41 studies in Sarcopenia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 247 Sarcopenia studies recruiting now, 154 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Sarcopenia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This pilot clinical trial aims to evaluate the safety and feasibility of an integrated fabric-type orthosis with muscle-mimicking and proprioception-enhancing functions in older adults with geriatric conditions affecting gait and balance. The wearable orthosis provides lower-limb assistance through a fabric-based actuation system and vibrotactile proprioceptive stimulation. Thirty participants aged 65 years or older will undergo gait, balance, proprioception, and electromyography assessments under three conditions: without the orthosis, with the orthosis powered off, and with the orthosis powered on. Outcome measures include gait performance, postural sway, one-leg standing balance, joint position sense, muscle activation, physiological responses, fatigue, and device-related adverse events. The study is designed as an exploratory pilot trial to assess the clinical applicability, usability, and safety of the wearable assistive device in geriatric patients.

03

Conditions studied

  • Sarcopenia
  • Older Adults (65 Years and Older)
  • Gait Analysis
  • Balance
  • Orthotic Device

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligibility for participation in the study requires that all the following criteria are met:

  1. Age: Participants must be 65 years of age or older.
  2. Comprehension and Compliance: Able to fully understand and comply with the instructions and study procedures.
  3. Mobility-Impacting Conditions: Must have at least one of the following conditions affecting mobility: (1)Sarcopenia:

    • Muscle Strength: Handgrip strength of \<28 kg for men and \<18 kg for women.
    • Muscle Function: Short Physical Performance Battery (SPPB) score of 8 or less.
    • Muscle Mass: Bioelectrical impedance analysis (BIA) showing muscle mass \<7.0 kg/m² for men and \<5.7 kg/m² for women. (2)Diabetes:
    • Diagnosed distal symmetric polyneuropathy.
    • Sensory impairments in toes or feet. (3)Knee Osteoarthritis:
    • Kellgren-Lawrence grade ≥2.
    • Persistent pain (≥3 months) with a severity of at least 3 on the Numerical Rating Scale (NRS).

Exclusion criteria

Exclusion Criteria:

Individuals meeting any of the following criteria will be excluded from study participation:

  1. Inability to Consent: Unable to provide or not willing to participate in the study procedures.
  2. Severe Sensory or Motion Limitations: Including severe visual or vestibular impairments that could increase the risk of falling.
  3. Communication Barriers: Significant hearing, speech, or language problems that would hinder communication with study personnel.
  4. Independent Walking Inability: Cannot walk independently without the aid of a walking device.
  5. Other Significant Diseases or Conditions:

    • Neurological disorders that affect walking ability (e.g., stroke, Parkinson's disease).
    • Orthopedic or musculoskeletal conditions severely affecting lower limb function.
    • Severe cardiovascular conditions including uncontrolled hypertension or heart failure.
    • Respiratory diseases requiring regular oxygen therapy.
    • Active cancer treatment or cancer treatment within the past 3 years (except basal cell carcinoma or localized prostate cancer).
    • Severe psychiatric disorders like schizophrenia or bipolar disorder.
  6. Other Exclusionary Factors:

    • Past severe orthopedic surgeries on lower limbs which might affect gait and mobility.
    • Severe back pain or any other condition affecting mobility not already listed.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Integrated Fabric-Type Orthosis Evaluation

    Participants will undergo gait, balance, proprioception, and electromyography assessments under three conditions: without the orthosis, with the orthosis powered off, and with the orthosis powered on. The wearable fabric-type orthosis provides muscle-mimicking lower-limb assistance and proprioception-enhancing vibrotactile stimulation for gait and balance support in older adults.

    Device: Integrated Fabric-Type Orthosis

Interventions

  • DeviceIntegrated Fabric-Type Orthosis

    A wearable fabric-type lower-limb orthosis integrating muscle-mimicking actuation and proprioception-enhancing vibrotactile stimulation. The device is designed to assist knee and ankle movements during gait and balance activities in older adults with gait and balance impairments. Participants will be evaluated under three conditions: without the orthosis, with the orthosis powered off, and with the orthosis powered on.

    Also known as: Soft Exosuit

06

What researchers measure

Primary outcomes

  1. Change in Blood Pressure From Before to After Functional Assessment

    Systolic and Diastolic blood pressure will be measured in millimeters of mercury (mmHg) before and after completion of the functional assessment, which includes gait and balance tests performed under the designated orthosis conditions.

    Time frame: Immediately before and after the functional assessment at each study visit

  2. Change in Heart Rate From Before to After Functional Assessment

    Heart rate will be measured in beats per minute (bpm) before and after completion of the functional assessment, which includes gait and balance tests performed under the designated orthosis conditions.

    Time frame: Immediately before and after the functional assessment at each study visit

  3. Change in Perceived Exertion From Before to After Functional Assessment

    Perceived exertion will be assessed using the Borg Scale before and after completion of the functional assessment. Higher scores indicate greater perceived exertion.

    Time frame: Immediately before and after the functional assessment at each study visit

  4. Change in Pain Intensity From Before to After Functional Assessment

    Pain intensity will be assessed using the Numeric Rating Scale (NRS) before and after completion of the functional assessment. Scores range from 0 to 10, with higher scores indicating greater pain intensity.

    Time frame: Immediately before and after the functional assessment at each study visit

Secondary outcomes

  1. 6-Minute Walk Test

    To evaluate walking endurance and functional mobility by measuring the maximum walking distance achieved within six minutes.

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  2. 10-Meter Walk Test

    To assess gait speed and short-distance walking performance under different orthosis conditions.

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  3. 20-Meter Walk Test

    To assess walking speed and gait performance over a longer walking distance.

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  4. Surface Electromyography

    To evaluate lower-limb muscle activation patterns during walking using surface electromyography (sEMG).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  5. Static One-Leg Standing Balance Test

    To evaluate static balance ability by measuring the duration participants can maintain single-leg standing.

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  6. Postural Sway

    To assess postural stability during quiet standing using center of pressure (COP)-based balance measurements.

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  7. Passive Joint Position Reproduction Test

    To evaluate proprioceptive accuracy by measuring passive knee joint position reproduction error.

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  8. Active Joint Position Reproduction Test

    To evaluate proprioceptive accuracy by measuring active knee joint position reproduction error.

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  9. Participant Satisfaction

    To assess participant satisfaction, comfort, perceived usability, and overall acceptance of the wearable orthosis.

    Time frame: Immediately post-brace activation (power on)

  10. Gait Speed

    Gait speed measured using the GAITRite system, reported in meters per second (m/s).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  11. Cadence

    Cadence measured using the GAITRite system, reported in steps per minute (steps/min).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  12. Step Time

    Step time measured using the GAITRite system, reported in seconds (s).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  13. Step Length

    Step length measured using the GAITRite system, reported in centimeters (cm).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  14. Stride Time

    Stride time measured using the GAITRite system, reported in seconds (s).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  15. Stride Length

    Stride length measured using the GAITRite system, reported in centimeters (cm).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  16. Single Support Time

    Single support time measured using the GAITRite system, reported in seconds (s).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  17. Double Support Time

    Double support time measured using the GAITRite system, reported in seconds (s).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  18. Stance Time

    Stance time measured using the GAITRite system, reported in seconds (s).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

  19. Swing Time

    Swing time measured using the GAITRite system, reported in seconds (s).

    Time frame: 1.Baseline (before brace application) 2.Immediately post-brace application (power off), 3.Immediately post-brace activation (power on)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 495 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 18 months is close to that.

Counting every sponsor, half of 506 studies reached it within 18 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
Nov 18, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945288
Collaborators
Ministry of Science and ICT, Republic of Korea
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jun 17, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

junghyun kim, prof
Contact
kiking0@naver.com
82+1088632341
hyungik shin, prof
study director · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion